Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JESUS E GUTIERREZ STONE

Allopathic & Osteopathic Physicians General Practice

NPI
1396990461
CMS profile
199270
Location
ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$14.09

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $14.09 1

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JESUS E GUTIERREZ STONE

NPI 1396990461 · CMS profile ID 199270

Allopathic & Osteopathic Physicians / General Practice

ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396990461?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JESUS E GUTIERREZ STONE, NPI 1396990461, CMS profile ID 199270. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396990461?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JESUS E GUTIERREZ STONE, NPI 1396990461, CMS profile ID 199270. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396990461?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JESUS E GUTIERREZ STONE, NPI 1396990461, CMS profile ID 199270, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1396990461?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $14.09 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.0902/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737536293 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $44.05 3
PY2020 $14.09 1
PY2021 $37.05 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021
Generated from
OP_DTL_GNRL_PGYR2021_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2021 Principal investigator $19,258.01 8
PY2020 Principal investigator $395,083.98 165
PY2019 Principal investigator $512,633.84 111

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

165 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $5,280.00 09/23/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
C3718-302 No dispute reported 06/30/2026 749682183
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $3,774.70 09/04/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
C3718-302 No dispute reported 06/30/2026 749682173
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $15,815.25 08/26/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
C3718-302 No dispute reported 06/30/2026 749682177
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $8,001.70 07/29/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
C3718-302 No dispute reported 06/30/2026 749678677
Principal investigator 1 Eisai Inc. $1,865.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137079
Principal investigator 1 Eisai Inc. $532.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137081
Principal investigator 1 Eisai Inc. $322.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137083
Principal investigator 1 Eisai Inc. $1,865.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137085
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137087
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137089
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137091
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137093
Principal investigator 1 Eisai Inc. $1,044.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137095
Principal investigator 1 Eisai Inc. $1,865.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137097
Principal investigator 1 Eisai Inc. $532.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137099
Principal investigator 1 Eisai Inc. $322.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137101
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137103
Principal investigator 1 Eisai Inc. $1,896.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137105
Principal investigator 1 Eisai Inc. $2,271.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137107
Principal investigator 1 Eisai Inc. $532.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137109
Principal investigator 1 Eisai Inc. $1,642.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137111
Principal investigator 1 Eisai Inc. $2,932.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137113
Principal investigator 1 Eisai Inc. $4,128.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137115
Principal investigator 1 Eisai Inc. $2,051.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137117
Principal investigator 1 Eisai Inc. $4,338.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137119
Principal investigator 1 Eisai Inc. $2,051.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137121
Principal investigator 1 Eisai Inc. $1,101.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137123
Principal investigator 1 Eisai Inc. $3,258.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137125
Principal investigator 1 Eisai Inc. $1,896.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137127
Principal investigator 1 Eisai Inc. $2,271.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137129
Principal investigator 1 Eisai Inc. $1,642.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137131
Principal investigator 1 Eisai Inc. $2,932.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137133
Principal investigator 1 Eisai Inc. $4,128.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137135
Principal investigator 1 Eisai Inc. $2,051.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137137
Principal investigator 1 Eisai Inc. $4,338.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137139
Principal investigator 1 Eisai Inc. $322.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137141
Principal investigator 1 Eisai Inc. $4,101.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137143
Principal investigator 1 Eisai Inc. $1,101.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137145
Principal investigator 1 Eisai Inc. $3,258.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137147
Principal investigator 1 Eisai Inc. $1,896.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137149
Principal investigator 1 Eisai Inc. $2,271.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137151
Principal investigator 1 Eisai Inc. $1,642.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137153
Principal investigator 1 Eisai Inc. $2,932.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137155
Principal investigator 1 Eisai Inc. $4,128.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137157
Principal investigator 1 Eisai Inc. $2,051.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137159
Principal investigator 1 Eisai Inc. $4,338.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137161
Principal investigator 1 Eisai Inc. $4,101.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137163
Principal investigator 1 Eisai Inc. $1,101.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137165
Principal investigator 1 Eisai Inc. $3,258.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137167
Principal investigator 1 Eisai Inc. $1,896.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137169
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137171
Principal investigator 1 Eisai Inc. $2,271.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137173
Principal investigator 1 Eisai Inc. $1,642.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137175
Principal investigator 1 Eisai Inc. $2,932.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137177
Principal investigator 1 Eisai Inc. $4,128.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137179
Principal investigator 1 Eisai Inc. $2,051.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137181
Principal investigator 1 Eisai Inc. $4,101.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137183
Principal investigator 1 Eisai Inc. $1,044.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137185
Principal investigator 1 Eisai Inc. $1,101.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137187
Principal investigator 1 Eisai Inc. $3,258.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137189
Principal investigator 1 Eisai Inc. $1,896.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137191
Principal investigator 1 Eisai Inc. $2,271.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137193
Principal investigator 1 Eisai Inc. $1,642.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137195
Principal investigator 1 Eisai Inc. $2,932.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137197
Principal investigator 1 Eisai Inc. $4,128.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137199
Principal investigator 1 Eisai Inc. $2,051.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137201
Principal investigator 1 Eisai Inc. $4,101.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137203
Principal investigator 1 Eisai Inc. $1,101.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137205
Principal investigator 1 Eisai Inc. $1,865.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137207
Principal investigator 1 Eisai Inc. $322.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137209
Principal investigator 1 Eisai Inc. $532.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137211
Principal investigator 1 Eisai Inc. $322.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137213
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137215
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137217
Principal investigator 1 Eisai Inc. $1,044.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137219
Principal investigator 1 Eisai Inc. $1,865.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137221
Principal investigator 1 Eisai Inc. $532.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137223
Principal investigator 1 Eisai Inc. $322.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137225
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137227
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137229
Principal investigator 1 Eisai Inc. $1,044.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137231
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137233
Principal investigator 1 Eisai Inc. $1,865.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137235
Principal investigator 1 Eisai Inc. $532.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137237
Principal investigator 1 Eisai Inc. $322.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137239
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137241
Principal investigator 1 Eisai Inc. $1,044.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137243
Principal investigator 1 Eisai Inc. $1,865.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137245
Principal investigator 1 Eisai Inc. $532.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137247
Principal investigator 1 Eisai Inc. $322.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137249
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137251
Principal investigator 1 Eisai Inc. $1,044.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137253
Principal investigator 1 Eisai Inc. $1,865.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137255
Principal investigator 1 Eisai Inc. $532.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137257
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137259
Principal investigator 1 Eisai Inc. $532.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137261
Principal investigator 1 Eisai Inc. $322.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137263
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137265
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137267
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137269
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137271
Principal investigator 1 Eisai Inc. $1,044.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137273
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137275
Principal investigator 1 Eisai Inc. $1,044.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137277
Principal investigator 1 Eisai Inc. $1,865.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137279
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137281
Principal investigator 1 Eisai Inc. $1,044.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137283
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137285
Principal investigator 1 Eisai Inc. $1,865.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137287
Principal investigator 1 Eisai Inc. $532.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137289
Principal investigator 1 Eisai Inc. $322.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137291
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137293
Principal investigator 1 Eisai Inc. $1,044.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137295
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137297
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137299
Principal investigator 1 Eisai Inc. $1,044.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137301
Principal investigator 1 Eisai Inc. $1,865.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137303
Principal investigator 1 Eisai Inc. $532.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137305
Principal investigator 1 Eisai Inc. $322.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137307
Principal investigator 1 Eisai Inc. $1,044.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137309
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137311
Principal investigator 1 Eisai Inc. $1,044.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137313
Principal investigator 1 Eisai Inc. $1,865.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137315
Principal investigator 1 Eisai Inc. $532.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137317
Principal investigator 1 Eisai Inc. $1,865.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137319
Principal investigator 1 Eisai Inc. $322.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137321
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137323
Principal investigator 1 Eisai Inc. $1,044.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137325
Principal investigator 1 Eisai Inc. $1,865.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137327
Principal investigator 1 Eisai Inc. $532.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137329
Principal investigator 1 Eisai Inc. $322.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137331
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137333
Principal investigator 1 Eisai Inc. $1,044.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137335
Principal investigator 1 Eisai Inc. $1,865.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137337
Principal investigator 1 Eisai Inc. $532.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137339
Principal investigator 1 Eisai Inc. $322.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137341
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137343
Principal investigator 1 Eisai Inc. $1,044.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137345
Principal investigator 1 Eisai Inc. $1,865.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137347
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137349
Principal investigator 1 Eisai Inc. $1,044.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137351
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137353
Principal investigator 1 Eisai Inc. $1,865.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137355
Principal investigator 1 Eisai Inc. $532.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137357
Principal investigator 1 Eisai Inc. $322.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137359
Principal investigator 1 Eisai Inc. $1,044.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137361
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137363
Principal investigator 1 Eisai Inc. $1,044.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137365
Principal investigator 1 Eisai Inc. $1,865.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137367
Principal investigator 1 Eisai Inc. $532.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137369
Principal investigator 1 Eisai Inc. $322.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137371
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137373
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137375
Principal investigator 1 Eisai Inc. $1,665.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137377
Principal investigator 1 Eisai Inc. $1,044.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137379
Principal investigator 1 Eisai Inc. $41,372.10 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137829
Principal investigator 1 Eisai Inc. $1,927.00 06/25/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749137841
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $8,921.25 05/13/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
C3718-302 No dispute reported 06/30/2026 749681033
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $21,080.51 03/20/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
C3718-302 No dispute reported 06/30/2026 749678687
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $18,043.20 03/04/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
C3718-302 No dispute reported 06/30/2026 749681037
Principal investigator 1 Eisai Inc. $1,176.00 02/27/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749136257
Principal investigator 1 Eisai Inc. $1,176.00 02/27/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749136259
Principal investigator 1 Eisai Inc. $1,176.00 02/27/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749136261
Principal investigator 1 Eisai Inc. $1,176.00 02/27/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749136263
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $16,834.27 02/03/2020 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
C3718-302 No dispute reported 06/30/2026 749678685